fda compounding semaglutide news september 2025 🚨 Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale of GLP-1 medications like and tirzepatide, signaling a major shift in how these Diabetes advocacy group discourages use

Folli F, Finzi G, Manfrini R, et al

Seek urgent medical attention if you experience severe abdominal pain, persistent vomiting, signs of an allergic reaction, chest pain, or dehydration, and inform the clinician of the substance used

The increased energy expenditure from glucagon receptor activation means your total daily expenditure is higher than it was on tirzepatide at equivalent body weight

30 days of free membership Same-day appointments 7 days a week Unlimited messages with your Care Team Exclusive discounts on lab tests Free memberships for your family Cancel anytime Paying with insurance $19.99 First month free Copay Visit price with insurance Paying without insurance $19.99 First month free $129 Visit price without insurance Initial visits are $129

These include IDegLira from Novo Nordisk, combining Tresiba (insulin degludec) and Victoza (liraglutide) into a once-daily injectable product ( and iGlarLixi from Sanofi, combining Lantus (insulin glargine) and Lyxumia (lixisenatide) into a similar product ( Both of the component drugs in IDegLira and the insulin glargine in iGlarLixi are already FDA approved, whereas lixisenatide is currently undergoing independent regulatory review

Anyone sensitive to caffeine or stimulants